

Supplementary Table S1. Clinical information for ovarian cancer patients whose tumors were evaluated for DGKA expression.

Sample #	Gender	Age	Tumor grade	Disease stage	Treatment history	Ethnicity	Histology	Response
1	F	71	poorly differentiated	III	Carboplatin/Paclitaxel	Caucasian	Papillary carcinoma, serous origin	Responded
2	F	59	poorly differentiated	III	Carboplatin/Paclitaxel/Bevacizumab	Asian	Serous carcinoma	Responded
3	F	67	Not available	IV	Carboplatin/Paclitaxel	Caucasian	Not available	Responded
4	F	72	poorly differentiated	IV	Carboplatin/Paclitaxel	Caucasian	Endometrioid carcinoma	Responded
5	F	59	Not available	III	Carboplatin/Paclitaxel	Caucasian	Epithelial	Responded
6	F	56	poorly differentiated	IV	Carboplatin/Paclitaxel	Asian	Papillary carcinoma, serous origin	Responded
7	F	71	poorly differentiated	III	Carboplatin/Paclitaxel	Caucasian	Carcinoma	Responded
8	F	65	poorly differentiated	III	Carboplatin/Paclitaxel/Bevacizumab	Caucasian	Papillary carcinoma, serous origin	Responded
9	F	60	Undifferentiated	III	Carboplatin/Paclitaxel	Caucasian	Serous cyst-adenocarcinoma	Responded
10	F	65	Undifferentiated	III	Carboplatin/Paclitaxel	Caucasian	Serous cyst-adenocarcinoma	Responded
11	F	46	poorly differentiated	II	Carboplatin/Paclitaxel	Asian	Mixed epithelial carcinoma	Responded
12	F	70	Well differentiated	IV	Carboplatin/Paclitaxel	Asian	Mucinous adenocarcinoma	Responded
13	F	69	poorly differentiated	III	Carboplatin/Paclitaxel	Caucasian	Serous carcinoma, sarcoma component	Responded
14	F	66	Not available	III	Carboplatin/Paclitaxel	Not available	Serous cyst-adenocarcinoma	Responded
15	F	87	Undifferentiated	III	Carboplatin/Paclitaxel	Caucasian	Carcinosarcoma	Responded
16	F	73	Not available	III	Carboplatin/Paclitaxel	Not available	Serous carcinoma	Responded
17	F	72	Poorly differentiated	IV	Carboplatin/Paclitaxel/Gemcitabine	Caucasian	Endometrioid carcinoma	Responded
18	F	85	Not available	IV	Carboplatin/Paclitaxel/Gemcitabine	Caucasian	Not available	Responded
19	F	58	Not available	III	Carboplatin/Paclitaxel	Caucasian	Not available	Responded
20	F	28	Not available	IV	Carboplatin/Paclitaxel/Bevacizumab	Caucasian	Not available	Responded
21	F	N/A	Not available	N/A	Carboplatin/Paclitaxel/Docetaxel	Not available	Not available	Responded
22	F	46	Poorly differentiated	III	Carboplatin/Paclitaxel	Caucasian	Papillary carcinoma, serous origin	No response
23	F	73	Not available	IV	Carboplatin/Paclitaxel	Caucasian	Not available	No response
24	F	62	Poorly differentiated	IV	Carboplatin/Paclitaxel	Caucasian	Papillary carcinoma, serous origin	No response
25	F	76	Not available	IV	Carboplatin/Paclitaxel	Not available	Adenocarcinoma	No response
26	F	55	Not available	III	Carboplatin/Paclitaxel	Caucasian	Clear cell carcinoma	No response